Literature DB >> 24149834

A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Efstratios Stratikos1, Angeliki Chroni.   

Abstract

Single amino acid mutations in apolipoprotein E (apoE) have been associated with the development of the rare kidney disease lipoprotein glomerulopathy (LPG). Although the genetic linkage to disease development is well established, the mechanism of pathogenesis is largely unknown, limiting therapeutic insight. Here, we summarize current knowledge in the field and focus on the possible effects of LPG-associated mutations on the structure of apoE. Recent findings have suggested that mutation-induced folding perturbations in apoE lead to structural destabilization and aggregation, effects that may underlie lipoprotein thrombi accumulation in the glomerulus, a hallmark of LPG. The recognition that structural destabilization may underlie the association between apoE mutations and LPG can be key for development of new innovative treatments for this rare disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24149834     DOI: 10.1007/s10157-013-0886-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  41 in total

Review 1.  Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.

Authors:  Takao Saito; Akira Matsunaga; Shinichi Oikawa
Journal:  Am J Kidney Dis       Date:  2006-02       Impact factor: 8.860

2.  A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.

Authors:  Andrew S Bomback; Huijuan Song; Vivette D D'Agati; Scott D Cohen; Alison Neal; Gerald B Appel; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2010-07-11       Impact factor: 5.992

3.  A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy.

Authors:  T Ogawa; K Maruyama; H Hattori; H Arai; I Kondoh; T Egashira; T Watanabe; Y Kobayashi; A Morikawa
Journal:  Pediatr Nephrol       Date:  2000-02       Impact factor: 3.714

4.  Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy.

Authors:  S Oikawa; A Matsunaga; T Saito; H Sato; T Seki; K Hoshi; K Hayasaka; H Kotake; H Midorikawa; A Sekikawa; S Hara; K Abe; T Toyota; H Jingami; H Nakamura; J Sasaki
Journal:  J Am Soc Nephrol       Date:  1997-05       Impact factor: 10.121

Review 5.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

6.  A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

Authors:  A Matsunaga; J Sasaki; T Komatsu; K Kanatsu; E Tsuji; K Moriyama; T Koga; K Arakawa; S Oikawa; T Saito; T Kita; T Doi
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

7.  Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons.

Authors:  Hung-Kai Chen; Zhaoping Liu; Anke Meyer-Franke; Jens Brodbeck; Rene D Miranda; James G McGuire; Michael A Pleiss; Zhong-Sheng Ji; Maureen E Balestra; David W Walker; Qin Xu; Dah-eun Jeong; Madhu S Budamagunta; John C Voss; Stephen B Freedman; Karl H Weisgraber; Yadong Huang; Robert W Mahley
Journal:  J Biol Chem       Date:  2011-12-12       Impact factor: 5.157

Review 8.  Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Med Chem       Date:  2012-10-05       Impact factor: 7.446

9.  Lipoprotein glomerulopathy: a pediatric case report.

Authors:  K Maruyama; H Arai; T Ogawa; S Tomizawa; A Morikawa
Journal:  Pediatr Nephrol       Date:  1997-04       Impact factor: 3.714

10.  A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy.

Authors:  Masahiro Hagiwara; Kunihiro Yamagata; Tsuneaki Matsunaga; Yoh Arakawa; Joichi Usui; Yoshio Shimizu; Kumi Aita; Michio Nagata; Akio Koyama; Bo Zhang; Akira Mastunaga; Keigiro Saku; Takao Saito
Journal:  Nephrol Dial Transplant       Date:  2007-10-28       Impact factor: 5.992

View more
  3 in total

1.  Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.

Authors:  Maria Katsarou; Efstratios Stratikos; Angeliki Chroni
Journal:  J Lipid Res       Date:  2018-10-11       Impact factor: 5.922

Review 2.  Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features.

Authors:  Irina Florina Tudorache; Violeta Georgeta Trusca; Anca Violeta Gafencu
Journal:  Comput Struct Biotechnol J       Date:  2017-06-06       Impact factor: 7.271

Review 3.  Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.

Authors:  Eduardo Cambruzzi; Karla Lais Pêgas
Journal:  J Bras Nefrol       Date:  2018-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.